{
    "paper_id": "8e5a17eee48c5bdcf6c93867963fc2a60a9c16cc",
    "metadata": {
        "title": "Lettre \u00e0 la r\u00e9daction",
        "authors": []
    },
    "abstract": [],
    "body_text": [
        {
            "text": "Regarding the COVID-19 outbreak, we propose an adaptation of current recommendations for clinical practice. Patients with suspected COVID-19 should be screened for the presence of the virus. If confirmed or highly suspected (clinically or CT-scan), any treatment must be postponed at least 15 days after the start of the symptoms and when the patient has recovered. Multidisciplinary tumor boards remain at your disposition for virtual discussion. Contact the manager of your local MDT. lung metastases without extra-thoracic extension and accessible to chest surgery; soft tissue sarcomas: second-lien treatment and beyond may be prescribed according to practice recommendations: oral treatments (pazopanib, or even regorafenib) may be preferred to limit the movement of patients for non-liposarcoma sarcoma. For liposarcomes: trabectedin or eribulin; GIST: the recommendations apply with imatinib and in the metastatic phase (then sunitinib and regorafenib); bone sarcomas with metastasis at diagnosis: classical first-line treatment, e.g. VDC-IE for Ewing sarcoma; metastatic relapse of bone sarcoma: topotecan and cyclophosphamide for Ewing's sarcoma; no standard of care for osteosarcomas (discuss anti-angiogenic treatment, e.g. regorafenib or pazopanib).",
            "cite_spans": [],
            "ref_spans": [],
            "section": "English version"
        },
        {
            "text": "D\u00e9claration de liens d'int\u00e9r\u00eats : les auteurs d\u00e9clarent ne pas avoir de liens d'int\u00e9r\u00eats.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Financement : aucun."
        }
    ],
    "bib_entries": {
        "BIBREF0": {
            "ref_id": "b0",
            "title": "Bone sarcomas: ESMO-PaedCan-EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up",
            "authors": [
                {
                    "first": "P",
                    "middle": [
                        "G"
                    ],
                    "last": "Casali",
                    "suffix": ""
                },
                {
                    "first": "S",
                    "middle": [],
                    "last": "Bielack",
                    "suffix": ""
                },
                {
                    "first": "N",
                    "middle": [],
                    "last": "Abecassis",
                    "suffix": ""
                },
                {
                    "first": "H",
                    "middle": [
                        "T"
                    ],
                    "last": "Aro",
                    "suffix": ""
                },
                {
                    "first": "S",
                    "middle": [],
                    "last": "Bauer",
                    "suffix": ""
                }
            ],
            "year": 2018,
            "venue": "Ann Oncol",
            "volume": "29",
            "issn": "4",
            "pages": "79--95",
            "other_ids": {}
        },
        "BIBREF1": {
            "ref_id": "b1",
            "title": "Gastrointestinal stromal tumours: ESMO-EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up",
            "authors": [
                {
                    "first": "P",
                    "middle": [
                        "G"
                    ],
                    "last": "Casali",
                    "suffix": ""
                },
                {
                    "first": "N",
                    "middle": [],
                    "last": "Abecassis",
                    "suffix": ""
                },
                {
                    "first": "S",
                    "middle": [],
                    "last": "Bauer",
                    "suffix": ""
                },
                {
                    "first": "R",
                    "middle": [],
                    "last": "Biagini",
                    "suffix": ""
                },
                {
                    "first": "S",
                    "middle": [],
                    "last": "Bielack",
                    "suffix": ""
                }
            ],
            "year": 2018,
            "venue": "Ann Oncol",
            "volume": "29",
            "issn": "4",
            "pages": "68--78",
            "other_ids": {}
        },
        "BIBREF2": {
            "ref_id": "b2",
            "title": "Soft tissue and visceral sarcomas: ESMO-EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up",
            "authors": [
                {
                    "first": "P",
                    "middle": [
                        "G"
                    ],
                    "last": "Casali",
                    "suffix": ""
                },
                {
                    "first": "N",
                    "middle": [],
                    "last": "Abecassis",
                    "suffix": ""
                },
                {
                    "first": "S",
                    "middle": [],
                    "last": "Bauer",
                    "suffix": ""
                },
                {
                    "first": "R",
                    "middle": [],
                    "last": "Biagini",
                    "suffix": ""
                },
                {
                    "first": "S",
                    "middle": [],
                    "last": "Bielack",
                    "suffix": ""
                }
            ],
            "year": 2018,
            "venue": "Ann Oncol",
            "volume": "29",
            "issn": "4",
            "pages": "51--67",
            "other_ids": {}
        },
        "BIBREF3": {
            "ref_id": "b3",
            "title": "An update on the management of sporadic desmoid-type fibromatosis: a European Consensus Initiative between Sarcoma PAtients EuroNet (SPAEN) and European Organization for Research and Treatment of Cancer (EORTC)/Soft Tissue and Bone Sarcoma Group (STBSG)",
            "authors": [
                {
                    "first": "B",
                    "middle": [],
                    "last": "Kasper",
                    "suffix": ""
                },
                {
                    "first": "C",
                    "middle": [],
                    "last": "Baumgarten",
                    "suffix": ""
                },
                {
                    "first": "J",
                    "middle": [],
                    "last": "Garcia",
                    "suffix": ""
                },
                {
                    "first": "S",
                    "middle": [],
                    "last": "Bonvalot",
                    "suffix": ""
                },
                {
                    "first": "R",
                    "middle": [],
                    "last": "Haas",
                    "suffix": ""
                }
            ],
            "year": 2017,
            "venue": "Ann Oncol",
            "volume": "28",
            "issn": "",
            "pages": "2399--408",
            "other_ids": {}
        },
        "BIBREF6": {
            "ref_id": "b6",
            "title": "5 Centre L\u00e9on-B\u00e9rard",
            "authors": [],
            "year": null,
            "venue": "Surgical Oncology Departement",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {}
        }
    },
    "ref_entries": {
        "TABREF0": {
            "text": "Nous proposons compte-tenu de l'urgence sanitaire une adaptation des recommandations th\u00e9rapeutiques. La pr\u00e9sence du virus doit \u00eatre recherch\u00e9e chez les patients avec suspicion d'infection COVID-19 (crit\u00e8res cliniques et/ou scanographiques). L e traitement doit alors \u00eatre d\u00e9cal\u00e9 de 15 jours \u00e0 partir du d\u00e9but des sympt\u00f4mes, si le patient est asymptomatique. Les r\u00e9unions de concertation pluridisciplinaire labellis\u00e9es restent \u00e0 la disposition de chacun. Il est pr\u00e9f\u00e9rable d'\u00e9changer par t\u00e9l\u00e9conf\u00e9rence ou visioconf\u00e9rence. N'h\u00e9sitez pas \u00e0 contacter le responsable de la RCP Sarcome locale : https:// expertisesarcome.org/centres-experts-par-region/.GIST  \u00e0 haut risque de rechute, initier le traitement adjuvant par imatinib. Pour les formes m\u00e9tastatiques: sarcomes des tissus mous : en phase m\u00e9tastatique, le traitement de premi\u00e8re ligne reste une chimioth\u00e9rapie avec doxorubicine, avec facteurs de croissances syst\u00e9matiques : mais proposition de polychimioth\u00e9rapie par doxorubicine et dacarbazine si l\u00e9iomyosarcome avec m\u00e9tastases pulmonaires limit\u00e9es sans extension extra-thoracique et accessibles \u00e0 une chirurgie thoracique, et proposition de polychimioth\u00e9rapie par doxorubicine et ifosfamide pour les autres histologies avec m\u00e9tastases pulmonaires limit\u00e9es sans extension extra-thoracique et accessibles \u00e0 une chirurgie thoracique) ; sarcomes des tissus mous : les traitements des deuxi\u00e8me ligne et au-del\u00e0 peuvent \u00eatre prescrits selon les recommandations de pratique habituelle : les traitements par voie orale (pazopanib, voire regorafenib) peuvent \u00eatre privil\u00e9gi\u00e9s pour limiter les d\u00e9placement des patients pour les sarcomes non liposarcome. Pour les liposarcomes : trabectedin ou eribuline ; GIST : les recommandations s'appliquent avec imatinib et en phase m\u00e9tastatique (pour sunitinib et r\u00e9gorafenib) ; sarcomes osseux d'embl\u00e9e m\u00e9tastatiques : ost\u00e9osarcomes et sarcomes d'Ewing d'embl\u00e9e m\u00e9tastatique (traitement de premi\u00e8re ligne classique, par exemple VDC-IE pour les sarcomes Ewing) ; rechute m\u00e9tastatique des sarcomes osseux : topotecan et cyclophosphamide pour les sarcomes d'Ewing ; pas de standard th\u00e9rapeutique pour les ost\u00e9osarcomes : discuter un traitement anti-angiog\u00e9nique.",
            "latex": null,
            "type": "table"
        }
    },
    "back_matter": []
}